1. Trends in cancer-targeted antibody–drug conjugates

   • François-Clément Bidard
   • Olivier Trédan

   Review 13 November 2013 Pages: 1 - 8

   

2. Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer

   • Luís León
   • Roberto García-Figueras
   • Carmen Sebastiá

   Review 12 December 2013 Pages: 9 - 24

   

3. Caffeic acid phenylethyl ester and MG132, two novel nonconventional chemotherapeutic agents, induce apoptosis of human leukemic cells by disrupting mitochondrial function

   • Victoria Cavaliere
   • Daniela L. Papademetrio
   • Elida M. C. Álvarez

   Original Research 22 February 2013 Pages: 25 - 42

   

4. EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer

   • Yogesh K. Vashist
   • Florian Trump
   • Jakob R. Izbicki

   Original Research 02 February 2013 Pages: 43 - 52

   

5. Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin

   • Hong Zhang
   • Shun-Dong Dai
   • Chao-Liu Dai

   Original Research 20 February 2013 Pages: 53 - 61

   

6. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma

   • Laura M. Alwan
   • Kenneth Grossmann
   • Jeffrey A. Gilreath

   Original Research 23 April 2013 Pages: 63 - 71

   

7. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

   • Swati Sikaria
   • Josefine Heim-Hall
   • Monica Mita

   Original Research 21 February 2013 Pages: 73 - 79

   

8. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature

   • Amaury Daste
   • Marine Gross-Goupil
   • Alain Ravaud

   Day-to-Day Practice 03 January 2013 Pages: 81 - 84

   

9. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer

   • Mark Sanford

   Adis Drug Evaluation 26 March 2014 Pages: 85 - 94